-
Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication
Recent Clinical Trial Findings Suggest Use Of The Weight-Loss Medicine Belviq Increased Risk Of Cancers (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq…
-
Are Zantac NDMA Levels Increased By Heat Exposures During Shipping And Storage?
This Theory Would Explain Why NDMA Was Not Found To Be A Problem At Zantac Manufacturing Sites (Posted by Tom Lamb at DrugInjuryWatch.com) The fact that Zantac contains NDMA (nitrosamine impurity called…
-
Gilenya Birth Defects Warnings Issued By Drug Safety Regulators In Canada And Europe — But Not By FDA In The US
Gilenya Increased Risk of Major Congenital Malformations Such As Renal / Kidney And Musculoskeletal Abnormalities, Atrial Septal Defects (Posted by Tom Lamb at DrugInjuryWatch.com) On December 19, 2019 Health Canada issued a…
-
Hemophilia Drug Hemlibra: Adverse Events Reports And Patient Deaths Raise Some Concerns
November 2019 NEJM Letter Points Out Possible Public Health Issue For Hemlibra Used By Hemophilia A Patients (Posted by Tom Lamb at DrugInjuryWatch.com) We recently learned about drug safety issues involving Hemlibra…
-
Zantac FDA Warning In September 2019 Leads To Lawsuits For Patients Diagnosed With Cancer
Cases Involve Stomach, Colon, Rectal, Bladder, Kidney, And Pancreatic Cancers Diagnosed After Taking Zantac (Posted by Tom Lamb at DrugInjuryWatch.com) Zantac cancer lawsuits are being filed for patients diagnosed with certain types…
-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
